A registrational trial of Abexinostat in treatment of hematological and solid tumors
Latest Information Update: 31 May 2017
Price :
$35 *
At a glance
- Drugs Abexinostat (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Registrational; Therapeutic Use
- Sponsors Xynomic Pharmaceuticals
- 31 May 2017 New trial record
- 22 May 2017 According to a Xynomic Phatrmaceuicals media release, the company plans to initiate this trial in 2H 2017.